| dc.contributor.author | Einhorn, Thomas A | en_US |
| dc.date.accessioned | 2012-01-12T17:39:15Z | |
| dc.date.available | 2012-01-12T17:39:15Z | |
| dc.date.issued | 2002-10-21 | en_US |
| dc.identifier.citation | Einhorn, Thomas A. "Cox-2: Where are we in 2003? - The role of cyclooxygenase-2 in bone repair" Arthritis Research & Therapy 5(1): 5-7. (2002) | en_US |
| dc.identifier.issn | 1478-6362 | en_US |
| dc.identifier.uri | http://hdl.handle.net/2144/3416 | |
| dc.description.abstract | Prostaglandins are important mediators of bone repair, and cyclooxygenases are required for prostaglandin production. Data from animal studies suggest that both non-specific and specific inhibitors of cyclooxygenases impair fracture healing but that this is due to the inhibition of COX-2 and not COX-1. Although these data raise concerns about the use of COX-2-specific inhibitors as anti-inflammatory or anti-analgesic drugs in patients undergoing bone repair, clinical reports have been inconclusive. Because animal data suggest that the effects of COX-2 inhibitors are both dose-dependent and reversible, in the absence of scientifically sound clinical evidence it is suggested that physicians consider short-term administration or other drugs in the management of these patients. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | BioMed Central | en_US |
| dc.subject | Bone repair | en_US |
| dc.subject | Cyclooxygenase-2 | en_US |
| dc.subject | Fracture healing | en_US |
| dc.subject | Non-steroidal anti-inflammatory drugs | en_US |
| dc.subject | Prostaglandins | en_US |
| dc.title | Cox-2: Where Are We in 2003? - The Role of Cyclooxygenase-2 in Bone Repair | en_US |
| dc.type | article | en_US |
| dc.identifier.doi | 10.1186/ar607 | en_US |
| dc.identifier.pubmedid | 12716441 | en_US |
| dc.identifier.pmcid | 154427 | en_US |